14 Nov, EOD - Indian

SENSEX 77580.31 (-0.14)

Nifty 50 23532.7 (-0.11)

Nifty Bank 50179.55 (0.18)

Nifty IT 42390.85 (0.05)

Nifty Midcap 100 54043.1 (0.45)

Nifty Next 50 67408.65 (0.46)

Nifty Pharma 21752 (-0.26)

Nifty Smallcap 100 17601.05 (0.81)

14 Nov, EOD - Global

NIKKEI 225 38642.91 (0.28)

HANG SENG 19426.34 (-0.05)

S&P 5912 (0.06)

LOGIN HERE

Brooks Laboratories Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 533543 | NSE Symbol : BROOKS | ISIN : INE650L01011 | Industry : Pharmaceuticals |


Chairman's Speech

Dear Shareholders,

I greet you all to the 20th AGM of Brooks Laboratories Limited.

It's my pleasure to share with you that Brooks Steriscience Limited, Subsidiary of your Company got its first AN DA approval of injection Meropenem a few days back which makes this facility at Vadodara a USFDA approved facility. We plan to launch injection Meropenem in US market by October / November 2022. This shall add lots of strength to your Company.

We are also in process of finalizing our sale agreements of Meropenem in all major European Countries as we already have got approval of this product in all 30 EU Countries of Europe including UK.

We also expect more AN DA approvals this year which shall augment immediate business of the Company.

We shall also be able to commission our API facility of Carbapenems in coming months, it will resolve all supply chain issues, reducing our dependency on foreign markets for API & making us much more self- reliant in creating stable business and thus value to your Company.

On domestic front, last 5 months have seen an unprecedented slump in pharmaceutical sales, this trend is prevalent post COVID-19 throughout the country including most global markets, but looks like worst is over and again we started picking up sales in both our critical care division and in exports. We, also have increased our focus in exports by initiating registrations in African and LTAM Countries. As we started focusing on these markets, we are hopeful of getting results in coming years by making us less dependant on contract manufacturing business in domestic markets. Our focus is nowon our own exports and on our own domestic marketing of critical care products.

Though USFDA or U KM HRA approvals a re not small steps for any Company, especially in injectable segment. Our endeavour this year is now to create business volumes in these markets through our recent approvals in these markets.

Before concluding I once again sincerely thank all our valuable shareholders, our business partners and all dedicated employees of our Company.

I wish and pray great health & wealth for all reading this message.

Place: Mumbai Atul Ranchal
Date: 03.09.2022 Chairman
Brooks Laboratories Ltd.